Literature DB >> 8388232

Analysis of the tumorigenic potential of common marmoset lymphoblastoid cells expressing a constitutively activated c-myc gene.

N A Hotchin1, N Wedderburn, I Roberts, J A Thomas, J A Bungey, B Naylor, D H Crawford.   

Abstract

The respective roles of Epstein-Barr virus (EBV) and c-myc in the pathogenesis of endemic Burkitt's lymphoma (BL) are unclear. In order to help resolve the question whether constitutive expression of the c-myc gene in an EBV-immortalised B cell is sufficient to induce a tumorigenic phenotype, B cells from a common marmoset (Callithrix jacchus) were immortalised with EBV, transfected with a constitutively activated c-myc gene and inoculated into the host animals. Despite the cell line transfected with c-myc displaying enhanced growth characteristics, in vitro and in vivo experiments demonstrated that this was not sufficient to induce a tumorigenic phenotype. This supports our previous findings with EBV-immortalised human B cells transfected with an activated c-myc gene (Hotchin et al., 1990).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388232      PMCID: PMC1968471          DOI: 10.1038/bjc.1993.172

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  43 in total

1.  Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells.

Authors:  M Rowe; H S Evans; L S Young; K Hennessy; E Kieff; A B Rickinson
Journal:  J Gen Virol       Date:  1987-06       Impact factor: 3.891

2.  Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein.

Authors:  D A Thorley-Lawson; E S Israelsohn
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

3.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

Authors:  D Wang; D Liebowitz; E Kieff
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

4.  Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts.

Authors:  H Land; A C Chen; J P Morgenstern; L F Parada; R A Weinberg
Journal:  Mol Cell Biol       Date:  1986-06       Impact factor: 4.272

5.  Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.

Authors:  D J Moss; I S Misko; S R Burrows; K Burman; R McCarthy; T B Sculley
Journal:  Nature       Date:  1988-02-25       Impact factor: 49.962

6.  Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus.

Authors:  V R Baichwal; B Sugden
Journal:  Oncogene       Date:  1988-05       Impact factor: 9.867

7.  Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts.

Authors:  L Lombardi; E W Newcomb; R Dalla-Favera
Journal:  Cell       Date:  1987-04-24       Impact factor: 41.582

8.  A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus.

Authors:  B Sugden; K Marsh; J Yates
Journal:  Mol Cell Biol       Date:  1985-02       Impact factor: 4.272

9.  Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product.

Authors:  G I Evan; G K Lewis; G Ramsay; J M Bishop
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

10.  Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.

Authors:  M Rowe; D T Rowe; C D Gregory; L S Young; P J Farrell; H Rupani; A B Rickinson
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

View more
  1 in total

1.  Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts.

Authors:  G Cutrona; M Ulivi; F Fais; S Roncella; M Ferrarini
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.